Dr. Jayaram Chigurupati
Jayaram Chigurupati (JAY)
has a Ph.D. in genetics (1988) and an MBA from Cornell (1994). His last assignment was as Executive Vice President of Dr. Reddy’s Laboratories Limited. In that position, he started and managed its biotechnology and oncology strategic business units as well as managed marketing in emerging markets around the world including Russia, China, and Brazil. All these SBUs have grown to become critical assets for Dr. Reddy’s.

Jayaram is either a promoter/controlling shareholder/CEO of the following entities:

Zenotech Laboratories Limited (
Hemarus LLC (

Agriculture and Crop Genetics
Trimurti Plant Sciences (

Techtran Polylenses Limited (

Financial Services
Coastal Local Area Bank Limited (
First Bank of the Palm Beaches (
Cypress Trust Company (

Media and Entertainment
Express TV (

Dr. Denis Broun
Dr. Denis Broun
obtained his Masters in Biomathematics (1977) and Medical Doctor Degree (1981) from the University of Paris. He then specialized in Tropical Medicine from Institute Leon Mob, University of Paris, 1982. He is also Diploma cum magna laude of the Paris Institute of Political Sciences, 1984.Denis Broun is presently the UNAIDS Regional Director for Europe and Central Asia. He earlier assignment was UNAIDS Country Coordinator, India. He has an extensive background in donor coordination and more than 15 years of experience in public health. His previous positions as Program Manager and then as Director of Department of Resource Mobilization at WHO (1998 to 2000), Chief of Health and Special Advisor to the Executive Director at UNICEF (1996 and 1998), Health Financing Specialist and Senior Health Specialist at the World Bank (1991 and 1996) have involved inter-agency communication and coordination in fields ranging from infectious diseases to child health. Dr. Broun has also managed all aspects of health policy planning and development. He has extensive experience in project design and management. Dr. Broun has particular expertise in public/private partnerships and private sector collaboration, donor coordination, and has extensive international experience. He joined the Board of Hemarus Therapeutics Limited from December, 2013.

Mr. Dipak Chattaraj
Mr. Dipak Chattaraj
retired as the Chairman of Ranbaxy Inc., USA and President (Corporate Development & Strategy), Ranbaxy Laboratories Ltd on December 31, 2010. He was instrumental in setting up the trend setting Ranbaxy’s US and Canada operations from their very inception as the President and CEO. In 2005, he relinquished the day to day responsibilities of these operations to take up the Corporate Development role for Ranbaxy Laboratories to drive the Company to the high growth verticals of biotechnology, vaccines and oncology etc. following the M&A and licensing routes. In this role he was also responsible for corporate strategy and planning.

Prior to joining Ranbaxy in 1991, Mr. Dipak was with the State Trading Corporation of India Ltd. having joined them as a Management Trainee in 1972. With STC, he played a pioneering role in organizing the then nascent exports of pharmaceuticals exports from India besides being integrally involved in the imports of pharmaceutical substances and intermediates for the entire Indian industry.

Dipak holds a masters degree in economics. He has travelled extensively through all the continents in pursuit of global business opportunities not only in pharmaceuticals but in other areas, both commodities and manufactured products.

Mr. Dipak joined the Board of Hemarus Therapeutics Limited from February, 2013.

Mr. Hemang Harish Raja
Mr. Hemang Harish Raja
did his graduation in commerce from University of Bombay in the year 1979. He did his MBA from Abilene Christian University (Now ‘Amber University’) Dallas and Advanced Management Programme (AMP) from Oxford U.K in 1997.

He has 30 years of experience in the field of finance, encompassing various aspects fund based, investment Banking & Capital Markets and Private Equity.

He worked as Country Advisor – India to Asia Growth Capital Advisors (AGCA) from August, 2010 till appointment of Director of the company. He previously worked as Head of India Operations from Sep, 2006 to March, 2007 with Ritchie Capital Management, LLC USA.

He worked as Managing Director and CEO of IL & FS Invest smart Limited (IIL)Group from May, 1990 to August 2006. He was a visiting faculty at Indian Institute of Management (IIM) at Calcutta and Bangalore.

Mr. Hemang Harish Raja joined the Board of Hemarus Therapeutics Limited from August 2014.

Dr. Uma Devi Komath
Dr. Uma Devi Komath
has MSc in Biochemistry (1984, Hyderabad Central University), Ph.D in Protein chemistry (CCMB), DBT Post Doc fellow and CSIR Research Associate with a combined post doctoral experience of 4 years.

She worked as Vice President (Research and Technical Services) at Zenotech Laboratories Ltd and Successfully oversaw three recombinant therapeutic proteins through development, production, regulatory approvals and commercial launch (G-CSF, GM-CSF, IL-2; brand names Nugraf, Macrogen and Recil respectively) and two biosimilar monoclonal antibodies (Rituximab and Etanercept) till clinical trials stage.

She also worked as Senior Manager, Biotech R&D at Dr. Reddy’s Laboratories Ltd. And conducted and trained a team for protein purification activities forvarious biosimilar therapeutic proteins like Filgrastim (G-CSF), GH, EPO, GM-CSF and TNF alpha and diagnostic proteins like HIV p24 and gp41 and initiated proteomic profiling of cancer tissues at Zenovus (a subsidiary of DRL).

Dr. Uma Devi Komath has joined the Board of Hemarus Therapeutics Limited in September, 2014.

Copyrights © Hemarus. All Rights Reserved. Home R & D Manufacturing Products Board Careers Plasma Collection Contact Us